<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509184</url>
  </required_header>
  <id_info>
    <org_study_id>MIR 2006-001212-72</org_study_id>
    <nct_id>NCT00509184</nct_id>
  </id_info>
  <brief_title>Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma</brief_title>
  <acronym>MIR</acronym>
  <official_title>Therapy of Nodal Follicular Lymphoma (Grade I/II) Clinical Stage I or II Using Involved Field Radiotherapy in Combination With Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klaus Herfarth - Dr. J. Debus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Low Grade Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination of involved field radiotherapy for the control of macroscopic disease and CD20
      antibody Rituximab for the control of microscopic remainders in other regions in patients
      with early stage nodal follicular lymphoma /grade I or II). Evaluation of DFSl and toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MIR (Mabthera(R) and Involved field Radiation) study is a prospective multicenter trial
      combining systemic treatment with the anti CD20 antibody Rituximab (Mabthera(R)) in
      combination with involved field radiotherapy (30 - 40 Gy). This trial aims at testing the
      combination's efficacy and safety with an accrual of 85 patients.Primary endpoint of the
      study is progression free survival. Secondary endpoints are response rate to Rituximab,
      complete remission rate at week 18, relapse rate, relapse pattern, relapse free survival,
      overall survival, toxicity and quality of life.

      More details: Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K. Treatment of limited stage
      follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a
      prospective multicenter Phase II trial-MIR trial. BMC cancer. 2011; 11: 87.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to Rituximab</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CR</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (CTC Vers. 3)</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate, Relapse pattern, DSF</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">85</enrollment>
  <condition>Lymphoma, Malignant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2, weekly (4 weeks), repeated after 4 weeks gap</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  verified follicular lymphoma grade 1 or 2

          -  only nodal involvement (incl. Waldeyer) clinical stage I or II

          -  largest tumor ≤ 7 cm

          -  adequate bone marrow reserves

        Exclusion Criteria:

          -  ECOG &gt;2

          -  Follicular lymphoma grade 3

          -  buky disease (&gt;7 cm)

          -  involvement of the spleen

          -  neoplasia in PMH (except: basalioma, spinalioma)

          -  Immunodeficiency syndromes, viral hepatitis, connective tissue disease

          -  severe psychiatric disease

          -  pregnancy or breast feeding

          -  known allergies against foreign proteins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Herfarth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin-Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Buch</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg (Campus Mannheim)</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.glsg.de</url>
    <description>German low grade lymphoma study group</description>
  </link>
  <link>
    <url>http://www.lymphome.de</url>
    <description>German network for malignant lymphomas</description>
  </link>
  <reference>
    <citation>Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer. 2011 Feb 26;11:87. doi: 10.1186/1471-2407-11-87.</citation>
    <PMID>21352561</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>July 21, 2013</last_update_submitted>
  <last_update_submitted_qc>July 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Klaus Herfarth - Dr. J. Debus</investigator_full_name>
    <investigator_title>Prof. Dr. K. Herfarth</investigator_title>
  </responsible_party>
  <keyword>untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

